Instrument Inactif

Communiqués Isofol Medical AB (publ) Nasdaq Stockholm

Actions

SE0009581051

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Isofol's Chief Financial Officer to leave the company	12/06	AQ
Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin	24/05	AQ
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024	08/05	AQ
Isofol Medical () : publishes interim report, January-March 2024	08/05	PU
Isofol Medical AB (publ) publishes interim report, January–March 2024	08/05	AQ
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023	16/04	AQ
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)	05/04	AQ
Isofol Medical : Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19/03	PU
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19/03	AQ
Isofol presents a clinical development plan for arfolitixorin	19/03	AQ
Isofol Medical : invites to investor meeting on March 19	01/03	PU
Isofol Medical AB (publ) publishes year-end report, January - December 2023	20/02	AQ
Isofol's Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19	14/02	AQ
Isofol appoints Magnus Hurst as new Chief Financial Officer	10/01	AQ
Isofol appoints Petter Segelman Lindqvist as new CEO	09/01	AQ
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024	04/01	AQ
Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects	28/12	AQ
Isofol's board of directors announces its position on minority shareholder's proposal ahead of extraordinary general meeting	13/12	AQ
Isofol has received the first results from laboratory tests of arfolitixorin	07/12	AQ
Isofol is liquidating a subsidiary	01/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Isofol Medical AB (publ) Nasdaq Stockholm

Actions

SE0009581051

Communiqués

Filtres